江苏恩华药业股份有限公司 第六届董事会第十八次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，对公告的虚假记载、误导性 陈述或重大遗漏负连带责任。 江苏恩华药业股份有限公司（以下简称：公司）第六届董事会第十八次会议于 2025 年 4 月 18 日在徐州市经济技术开发区龙湖西路 31 号恩华科技大厦 20 楼会议室召开，会议通知已 于 2025 年 4 月 7 日以专人送达、传真、电子邮件等方式送达给全体董事、监事和高级管理人 员。本次会议应到董事 8 名，实到董事 8 名。公司监事和高级管理人员亦列席本次会议。本 次会议由董事长孙彭生先生召集并主持。本次会议的召集、召开程序符合有关法律法规和公 司章程的规定。 证券代码：002262 证券简称：恩华药业 公告编号：2025-022 一、董事会会议召开情况 二、董事会会议审议情况 1、会议以8票赞成、0票反对、0票弃权的表决结果审议通过了《2025年第一季度报告》。 董事会全体董事保证公司《2025年第一季度报告》内容的真实、准确、完整，不存在虚 假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 《2025年第一季度报告》（公告编号 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥1,510,888,789.07, representing an increase of 11.29% compared to ¥1,357,565,651.12 in the same period last year[5] - Net profit attributable to shareholders was ¥300,705,740.93, up 13.35% from ¥265,282,248.03 year-on-year[5] - Basic and diluted earnings per share rose by 15.38% to ¥0.30 from ¥0.26 in the same period last year[5] - Net profit for the current period was ¥300,639,634.41, representing a 13.6% increase from ¥264,638,776.41 in the previous period[21] - Basic earnings per share for the current period were ¥0.30, up from ¥0.26 in the previous period[22] Cash Flow and Liquidity - The net cash flow from operating activities increased by 36.69% to ¥319,272,299.47, compared to ¥233,582,275.30 in the previous year[5] - The company reported a significant increase in cash and cash equivalents, reaching CNY 2,082,237,101.86, up from CNY 1,416,389,329.18 at the beginning of the period, representing a growth of approximately 47%[16] - Cash inflow from investment activities amounted to ¥2,295,107,170.32, compared to ¥1,011,725,654.77, showing a significant increase of 126.67%[24] - Cash and cash equivalents at the end of the period totaled ¥1,926,390,521.55, an increase from ¥1,571,753,981.33, reflecting a growth of 22.56%[24] - Cash outflow from financing activities decreased to ¥12,398,245.97 from ¥18,049,004.82, a reduction of 31.56%[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,869,023,396.87, a 5.08% increase from ¥8,440,005,655.95 at the end of the previous year[5] - The total liabilities increased to ¥1,276,276,509.68 from ¥1,166,489,878.17, reflecting a rise of 9.4%[18] - The company's equity attributable to shareholders rose to ¥7,619,618,940.41, compared to ¥7,300,321,724.48, an increase of 4.4%[18] Investment and Expenses - Research and development expenses increased by 33.88%, reflecting higher investment in R&D and stock incentive costs[12] - Investment income from financial products rose by 82.07%, attributed to increased short-term financial product returns[12] - Total operating costs amounted to ¥1,172,507,853.52, up from ¥1,036,808,322.12, reflecting a rise of 13.1%[20] - Cash paid for purchasing goods and services increased to ¥365,131,720.52 from ¥343,920,750.51, a rise of 6.67%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 33,514, with the largest shareholder holding 31.50% of the shares[11] - The major shareholders include Xu Zhou Enhua Investment Co., Ltd. holding 320,096,321 shares, representing a significant portion of the company’s equity[13] - The company’s actual controllers hold a combined 55.58% stake in Xu Zhou Enhua Investment Co., Ltd. and 16.42% in the company, ensuring substantial control[13] Other Financial Metrics - The company reported a decrease in financial expenses, with a net financial cost of -¥3,134,146.05, compared to -¥6,355,726.56 in the previous period[20] - Cash received from investment income rose to ¥18,089,170.32 from ¥6,725,654.77, an increase of 168.73%[24] - Cash received from tax refunds increased significantly to ¥346,253.96 from ¥19,865.69, a growth of 1647.73%[23] - The net increase in cash and cash equivalents was up 262.82%, driven by higher cash inflows from operating and investment activities[12]

恩华药业：2025年第一季度营收为15.11亿元，同比增长11.29%；净利润为3.01亿元，同比增长 13.35%。 ...

Summary of Conference Call Records Company and Industry Overview - The discussion primarily revolves around the pharmaceutical and medical device industries, with a focus on small-cap companies and their innovative capabilities. The emphasis is on the potential for significant investment returns from these smaller firms as they introduce world-class innovations [1][2]. Key Points and Arguments Innovation and Market Dynamics - The rise of world-class innovations from smaller companies is highlighted, suggesting that these firms are increasingly capable of delivering significant breakthroughs in technology and products, which can lead to substantial investment opportunities [1]. - The current state of small-cap companies in the Hong Kong stock market is described as severely undervalued, indicating a potential for significant price reversals and investment elasticity [2]. Clinical Trials and Product Development - There is a notable increase in the number of clinical trials being conducted by both new and established companies, with specific mention of companies like 百利链 and 克隆伯泰 showing promising stock performance and long-term value potential [3]. - The report mentions ongoing clinical trials in the oncology sector, particularly the oral formulations and their third-phase data, which are seen as key developments in the industry [2]. Equipment and Device Sector - The medical equipment sector is expected to experience growth due to the recovery of bidding processes and inventory adjustments, with companies like 联营, 开力, and 奥华 being highlighted as key players to watch [4]. - The report notes that the equipment industry is likely to see a positive growth trajectory in the first quarter of the year, driven by increased demand and inventory management [4]. Market Trends in Traditional Chinese Medicine - The traditional Chinese medicine sector is experiencing a downturn, with a projected decline in retail sales for 2024, particularly in categories like cold and flu medications [25][26]. - Despite the overall decline, certain products within the sector, such as 阿胶, are noted for their strong market performance, indicating a mixed outlook for the industry [27]. Investment Opportunities - The report suggests that there are significant investment opportunities in the pharmaceutical sector, particularly in companies with strong clinical capabilities and financial resources, which are expected to benefit from new regulatory measures and market dynamics [12][15]. - The potential for mergers and acquisitions in the life sciences sector is also discussed, with companies like 必得医药 and 奥普麦 actively pursuing strategic acquisitions to enhance their market positions [21]. Economic Indicators and Investment Climate - The investment climate for the biopharmaceutical sector is reported to be improving, with significant increases in investment amounts both domestically and internationally, indicating a robust growth outlook for the sector [18][19]. - The report highlights a positive trend in orders and revenue for the CXO sector, with expectations for many companies to return to double-digit growth in the coming years [19]. Other Important Insights - The introduction of new regulatory measures, such as the three-year data protection period for certain generic drugs, is expected to create a more favorable competitive environment for leading companies in the pharmaceutical industry [12][15]. - The report emphasizes the importance of monitoring the performance of small-cap companies and their innovative products, as they may present significant investment opportunities in the evolving market landscape [3][4]. This summary encapsulates the key insights and trends discussed in the conference call, providing a comprehensive overview of the current state and future outlook of the pharmaceutical and medical device industries.

Group 1 - Company Instech reported a net profit of 177 million yuan for 2024, a year-on-year increase of 28.15%, with a proposed cash dividend of 1.20 yuan per 10 shares [1] - Instech achieved an operating revenue of 1.185 billion yuan in 2024, representing a year-on-year growth of 24.45% [1] - The company specializes in the research, production, and sales of rare earth permanent magnet materials and applications [2] Group 2 - Company Junda reported a net loss of 106 million yuan for Q1 2025, transitioning from profit to loss, with a year-on-year revenue decline of 49.52% [3] - Junda's operating revenue for Q1 2025 was 1.875 billion yuan [3] - The company focuses on the research, production, and sales of photovoltaic cell products [4] Group 3 - Company Annada reported a net loss of 10.26 million yuan for Q1 2025, with a year-on-year revenue increase of 1.44% [5] - Annada's operating revenue for Q1 2025 was 473 million yuan [5] - The company specializes in titanium dioxide and iron phosphate products [6] Group 4 - Company Jiuzhou Pharmaceutical reported a net profit of 250 million yuan for Q1 2025, a year-on-year increase of 5.68% [7] - Jiuzhou's operating revenue for Q1 2025 was 1.49 billion yuan, reflecting a year-on-year growth of 0.98% [7] - The company provides custom research and production services for pharmaceutical companies and research institutions [8] Group 5 - Company Yitong Century won a 1.48 billion yuan contract for a 5G comprehensive maintenance project with Guangdong Unicom [9] - The project will enhance the company's business volume and expansion in Guangdong [9] - Yitong Century specializes in communication network technology services and solutions [10] Group 6 - Company Rijiu Optoelectronics reported a net profit of 67.47 million yuan for 2024, a year-on-year increase of 506.9%, with a proposed cash dividend of 2.00 yuan per 10 shares [10] - Rijiu's operating revenue for 2024 was 583 million yuan, representing a year-on-year growth of 22% [10] - The company focuses on the research, production, and sales of touch display application materials [11] Group 7 - Company Ruotong reported a net profit of 95.98 million yuan for 2024, a year-on-year increase of 0.91%, with a proposed cash dividend of 2.00 yuan per 10 shares [12] - Ruotong's operating revenue for 2024 was 408 million yuan, reflecting a year-on-year growth of 7.54% [12] - The company specializes in drilling and completion equipment for oil and gas [13] Group 8 - Company Shuangxiang reported a net profit of 472 million yuan for 2024, a year-on-year increase of 754.84%, with a proposed cash dividend of 1.50 yuan per 10 shares [14] - Shuangxiang's operating revenue for 2024 was 2.29 billion yuan, representing a year-on-year growth of 51.55% [14] - The company focuses on synthetic leather and optical-grade PMMA products [15] Group 9 - Company Xinfang Pharmaceutical reported a net profit of 101 million yuan for 2024, a year-on-year decrease of 64.70%, with a proposed cash dividend of 0.30 yuan per 10 shares [16] - Xinfang's operating revenue for 2024 was 6.032 billion yuan, reflecting a year-on-year decline of 6.63% [16] - The company is involved in medical services, pharmaceutical distribution, and manufacturing [17] Group 10 - Company Dongxing Medical reported a net profit of 97.42 million yuan for 2024, a year-on-year increase of 0.21%, with a proposed cash dividend of 6.00 yuan per 10 shares [18] - Dongxing's operating revenue for 2024 was 435 million yuan, reflecting a year-on-year growth of 0.40% [18] - The company specializes in surgical medical devices [19] Group 11 - Company Wuzhou Special Paper reported a net profit of 64.68 million yuan for Q1 2025, a year-on-year decrease of 51.56%, with an operating revenue of 1.989 billion yuan [20] - Wuzhou's operating revenue for Q1 2025 increased by 15.21% [20] - The company focuses on the research, production, and sales of mechanism paper and pulp [21] Group 12 - Company Jinrui Mining expects a net profit of 15.28 million yuan for Q1 2025, a year-on-year increase of 617.40% [22] - The company specializes in the production and sales of strontium salt products [23] Group 13 - Company Youyan New Materials expects a net profit of 60 million to 75 million yuan for Q1 2025, a year-on-year increase of 13076% to 16370% [24] - The company focuses on electronic films, precious metal materials, and rare earth materials [25] Group 14 - Company Guoli expects a net profit of 11 million to 13 million yuan for Q1 2025, a year-on-year increase of 164.38% to 212.45% [26] - The company specializes in urban infrastructure design, construction, and investment [27] Group 15 - Company Shenzhen Airport reported a passenger throughput of 5.5422 million in March, a year-on-year increase of 8.70% [28] - The airport's cargo throughput was 171,900 tons, reflecting a year-on-year growth of 14.51% [28] - The company is involved in aviation and related non-aviation businesses [29] Group 16 - Company Shenghui Integration reported an order balance of 2.117 billion yuan as of March 31, 2025, a year-on-year increase of 11.89% [30] - The company provides cleanroom engineering and electromechanical engineering services [31] Group 17 - Company Chengyi Pharmaceutical received a drug registration certificate for Mercaptopurine tablets [32] - The drug is applicable for various diseases including choriocarcinoma and acute lymphoblastic leukemia [32] Group 18 - Company Enhua Pharmaceutical initiated Phase I clinical trials for NH280105 capsules, targeting Alzheimer's disease [33] - The trial aims to assess the safety and pharmacokinetics of the drug [33] Group 19 - Company Lingang Steel proposed a share buyback of 50 million to 100 million yuan [34] - The company specializes in the production and development of metallurgical products [35] Group 20 - Company Fujia plans to repurchase shares worth 15 million to 30 million yuan [36] - The company focuses on smart cleaning appliances and key components [37] Group 21 - Company Mould Technology received a project designation letter for exterior parts from a luxury car client, with an estimated total sales of 2.07 billion yuan [38] - The project is expected to start mass production in April 2027 [38] Group 22 - Company Longxin General expects a net profit of 4.55 billion to 5.30 billion yuan for Q1 2025, a year-on-year increase of 76.65% to 105.77% [39] - The company specializes in motorcycles, engines, and general machinery products [40] Group 23 - Company Dongfang Securities reported a net profit of 1.436 billion yuan for Q1 2025, a year-on-year increase of 62.08% [41] - The company focuses on investment management and securities trading [42] Group 24 - Company Yalian Machinery plans to use up to 800 million yuan of idle funds for low-risk financial products [43] - The company specializes in the production of engineered wood production lines and equipment [44] Group 25 - Company Guanghua Technology reported a net loss of 205 million yuan for 2024, with total revenue of 2.589 billion yuan [45] - The company focuses on PCB chemicals and lithium battery materials [46] Group 26 - Company Boya Biotechnology plans to publicly transfer 80% of its subsidiary's equity for 213 million yuan [47] - The transaction aims to optimize resource allocation focusing on blood products [48] Group 27 - Company Darui Electronics plans to repurchase shares worth 30 million to 50 million yuan [49] - The company specializes in customized components and automation equipment [50] Group 28 - Company Hongying Intelligent plans to repurchase shares worth 30 million to 40 million yuan [51] - The company focuses on smart control products and assemblies [52] Group 29 - Company Guangku Technology announced a change in the upper shareholding structure of its controlling shareholder [53] - The operational activities of the company will not be materially affected [54] Group 30 - Company Dingjie Smart's application for convertible bond issuance has been accepted by the Shenzhen Stock Exchange [55] - The company provides digital and intelligent solutions for various industries [56]

证券代码：002262 证券简称：恩华药业 公告编号：2025-019 江苏恩华药业股份有限公司 关于取消2024年度股东大会部分子提案暨补充通知的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 江苏恩华药业股份有限公司（ 以下简称"公司"）第六届董事会第十六次会议于2025年3 月27日在徐州市经济技术开发区龙湖西路31号恩华科技大厦20楼会议室召开，会议决定于 2025年4月25日（星期五）召开2024年度股东大会。具体内容详见公司于2025年3月29日在 《证券时报》及巨潮资讯网（http://www.cninfo.com.cn）上披露的《关于召开2024年度股东大 会的通知》（公告编号：2025-014）。 孔徐生先生因其个人工作调整方面的原因于近日向公司董事会提出申请取消其作为公司 第七届董事会独立董事候选人资格，为此，公司于2025年4月11日召开了第六届董事会第十七 次（临时）会议，审议通过了《关于取消公司2024年度股东大会部分子提案的议案》，董事 会同意取消孔徐生先生作为公司第七届董事会独立董事候选人资格，同意取消2024年度股东 大会提案 ...

Core Viewpoint - The article emphasizes the importance of companies with high return on equity (ROE) in the A-share market, especially in the context of increasing external risks and market volatility. It highlights that companies maintaining a high ROE are likely to attract investment due to their stability and profitability [1][2]. Group 1: High ROE Companies - Seven A-share companies have maintained a net asset return rate (ROE) of over 15% for the past ten years, with foreign income accounting for less than 10% of their revenue [2][4]. - These companies are recognized for their strong market positions and competitive advantages, including excellent management, patented technologies, and industry leadership [2][4]. Group 2: Company Performance and Market Position - Guizhou Moutai and Haitian Flavoring are the leading companies in their respective industries, with market capitalizations exceeding 200 billion yuan [5]. - Tonghuashun, Shuanghui Development, and AVIC Optoelectronics also have significant market capitalizations, each exceeding 50 billion yuan, indicating their strong market presence [5]. - The net profit compound growth rates for companies like Enhua Pharmaceutical and Morning Glory have exceeded 10% over the past decade, showcasing their growth potential [5]. Group 3: Financial Performance - Tonghuashun reported a revenue of 4.187 billion yuan in 2024, a year-on-year increase of 17.47%, with a net profit of 1.823 billion yuan, up 30% [6]. - Guizhou Moutai is projected to achieve a revenue of 174.144 billion yuan in 2024, with a net profit of 86.228 billion yuan, reflecting a growth of 15.66% and 15.38% respectively [9]. Group 4: Institutional Investment - Guizhou Moutai has attracted significant institutional investment, with a net buy amounting to 1.317 billion yuan, indicating strong market confidence [9]. - Enhua Pharmaceutical also saw institutional net buying of 60.138 million yuan, reflecting positive market sentiment towards its growth strategy [10].

Group 1 - Enhua Pharmaceutical (002262.SZ) released its 2024 annual report on March 29, 2025, indicating that as of March 28, 2025, 162 institutional investors disclosed holding A-shares, totaling 438 million shares, which accounts for 43.14% of the total share capital [1] - The top ten institutional investors include Xuzhou Enhua Investment Co., Ltd., Hong Kong Central Clearing Limited, and several funds, with the top ten collectively holding 38.60% of the shares, a decrease of 1.15 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, Morgan Stanley's Yuyao Anhe Mixed A, increased its holdings, while eight funds, including China Europe Medical Health Mixed A and others, reduced their holdings, with a total decrease of 1.16% [2] - A total of 127 new public funds were disclosed this period, including several from Invesco Great Wall and others, while 33 funds were not disclosed this period, including various funds from Huatai-PineBridge [2] - Foreign investment sentiment showed a decrease in holdings from one foreign fund, Hong Kong Central Clearing Limited, with a reduction of 0.36% [2]

证券代码：002262 证券简称：恩华药业 公告编号：2025-013 江苏恩华药业股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，对公告的虚假记载、误导性 陈述或重大遗漏负连带责任。 江苏恩华药业股份有限公司（以下简称"公司"）第六届董事会第十六次会议和第六届监 事会第十四次会议审议通过了《关于会计政策变更的议案》，根据相关规定，本次会计政策 变更无需提交股东大会审议。现将有关情况公告如下： 一、本次会计政策变更概述 1、变更原因 根据（1）财政部于2023年10月25日发布的《关于印发<企业会计准则解释第17号>的通 知》（财会〔2023〕21号）（以下简称"准则解释第17号"）的规定，"关于流动负债与非流动负 债的划分"、"关于供应商融资安排的披露"、"关于售后租回交易的会计处理"的内容，该解释 规定自2024年1月1日起施行。（2）财政部于2023年8月1日发布的《企业数据资源相关会计处 理暂行规定》（财会11号），适用于符合企业会计准则相关规定确认为无形资产或存货等资产 的数据资源，以及企业合法拥有或控制的、预期会给企业带来经济利益的、但不满足资产确 认条件 ...

江苏恩华药业股份有限公司 关于会计师事务所 2024 年度履职情况评估报告 根据《国有企业、上市公司选聘会计师事务所管理办法》（财会[2023]4 号）有关要求，江 苏恩华药业股份有公司（以下简称"公司"）对立信会计师事务所（特殊普通合伙）（以下简称 "立信所"）2024 年审计过程中的履职情况进行了评估，具体情况如下： 一、2024 年年审会计师事务所基本情况 （一）资质条件 立信会计师事务所（特殊普通合伙）成立于 1927 年，复办于 1986 年，注册地址为上海市， 首席合伙人为朱建弟先生。立信所是国际会计网络 BDO 的成员所，长期从事证券服务业务，新 证券法实施前具有证券、期货业务许可证，具有 H 股审计资格，并已向美国公众公司会计监督 委员会（PCAOB）注册登记。截至 2024 年末，立信所拥有合伙人 296 名、注册会计师 2,498 名、 从业人员总数 10,021 名，签署过证券服务业务审计报告的注册会计师人数 743 名。 （二）会计师事务所执业记录 | 1、基本信息 | | --- | | 项目 | 姓名 | 注册会计师执业时 | 开始从事上市 | 开始在本所 | 开始为本公司提供审 ...